We utilize proprietary drug delivery technologies with application across therapeutic areas.

Acerus applies proprietary drug delivery technology platforms to existing molecules, to create innovative products that improve the patient experience. It is intended that these drug delivery technologies provide a safer, possibly more effective and more practical solution for drug administration than competitive products on the market, with application across various therapeutic areas.

Acerus has acquired or licensed the rights to two proprietary platforms and is pursuing the development and application of these technologies to several high value pharmaceutical compounds. These innovative drug delivery technology platforms consist of a bioadhesive nasal gel, currently used with NATESTO™ and TEFINA™, and the TriVair™ Deposition/Dispersion System, a unit dose dry powder inhaler and nasal dispersion system.